Mizuho Reiterates Buy on Axsome Therapeutics, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a $100 price target.
September 25, 2023 | 3:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics' stock rating has been reiterated as 'Buy' by Mizuho with a maintained price target of $100.
The reiteration of a 'Buy' rating by a reputable analyst like Graig Suvannavejh from Mizuho is a positive signal for Axsome Therapeutics. The maintained price target of $100 also indicates confidence in the company's future performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100